X4 Pharmaceuticals Posts $20.2M Q3 Net Loss
The Boston-based biotech reported third-quarter 2026 results and advanced plans for a Phase 2b trial of its mavorixafor candidate.
Updated on Nov. 4, 2026 in Corporate Finance
X4 Pharmaceuticals reported a third-quarter 2026 net loss of $20.2 million on total revenue of $2.9 million. The company ended the period with $187.7 million in cash, cash equivalents and marketable securities.
Why it matters
The results show a company spending on late-stage development while holding a sizable cash position and a new credit facility. Investors and Boston-area biotech watchers will track whether planned trial readouts stay on schedule.
The company reported Q3 2026 R&D expenses of $13.3 million and G&A expenses of $9.0 million, with R&D decreasing primarily due to reduced headcount from the 2025 restructuring. Results are compared against the quarter ended September 30, 2025, and the 4STEPS trial's timing is not yet confirmed beyond a first-participant target.
The players
X4 Pharmaceuticals
A Boston-based biopharmaceutical company developing mavorixafor for rare immune disorders, including chronic neutropenia.
K2 HealthVentures LLC
A healthcare-focused investment firm that provided the senior term loan facility to X4 Pharmaceuticals.
The details
X4 Pharmaceuticals secured a senior term loan facility of up to $150 million with K2 HealthVentures LLC and began planning a Phase 2b 4STEPS trial in approximately 25 patients. Enrollment in the 4WARD trial, reduced after a positive Type C meeting with the FDA, is expected to complete in the fourth quarter of 2026.
Timeline
December 31, 2025: Prior-year balance sheet comparison date.
September 30, 2026: Third-quarter 2026 reporting period ended.
Fourth quarter 2026: Expected completion of 4WARD trial enrollment.
First quarter 2027: Expected first participant enrollment in the 4STEPS trial.
Corporate Finance Context
The 4WARD enrollment reduction follows a positive Type C meeting with the FDA, a regulatory step that shapes trial size for companies advancing candidates toward approval. The new K2 HealthVentures facility adds to the debt financing options that rare-disease biotechs use to fund late-stage work.
Shareholders watching X4 should note that the company's cash position of $187.7 million and new $150 million credit facility determine how long operations can run before additional financing is needed. Retail investors tracking the stock can use the quarterly net loss figures to gauge how quickly the company is spending its reserves.
The takeaway
Biotech investors should compare a company's quarterly burn rate with its cash balance and debt terms to estimate runway. For X4, the combination of the $187.7 million cash position and the new term loan sets the window for its planned trial readouts.
What happens next
The 4WARD trial enrollment is expected to complete in the fourth quarter of 2026, with topline data expected in the first quarter of 2028.
Further reading
Explore more corporate finance coverage for context on how biotech companies fund late-stage trials.
Source note: This article includes information reported by The Manila times.
